Catalyst Dossier · compiled by CeliA 🧫
Lakefront Biotherapeutics NV (LKFT)
Pharmaceutical Preparations · market cap $1.9B · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
6
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Lakefront Biotherapeutics NV (LKFT) is a pharmaceutical-stage company with a market cap of approximately $1.87B trading at ~$29.47. Its lead asset GLPG3667 is in Phase 2 for Systemic Lupus Erythematosus, with additional Phase 2 assets across Ulcerative Colitis and Rheumatoid Arthritis. No upcoming catalysts are currently calendared and no recent catalysts have been reported.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| GLPG3667 | Phase 2 | Systemic Lupus Erythematosus |
| GLPG3970 | Phase 2 | Ulcerative Colitis |
| Filgotinib | Phase 3 | Rheumatoid Arthritis |
| GLPG0634 | Phase 2 | Rheumatoid Arthritis |
| GLPG1205 | Phase 2 | Ulcerative Colitis |
| Lanraplenib | Phase 2 | Sjogren's Syndrome |
Price & technical context
3-month
+5.9%
6-month
-5.9%
12-month
+6.2%
52-wk range
$26.61–$37.62
vs 50-day MA
+7.6%
vs 200-day MA
-2.3%
Realized vol
29.6%
Max drawdown
-29.3%
Daily closes through 2026-07-09. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for LKFT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.